title: Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In regard to Brown et al.
authors.affiliation: Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Shyam S
authors.initials: SS
authors.lastname: Rao
authors.affiliation: Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Jung Hun
authors.initials: JH
authors.lastname: Oh
authors.affiliation: Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Andrew
authors.initials: A
authors.lastname: Jackson
authors.affiliation: Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Deasy
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery*; D006801:Humans; D008175:Lung Neoplasms / Q000601:surgery*; D016634:Radiosurgery / Q000379:methods*